全文获取类型
收费全文 | 766篇 |
免费 | 87篇 |
国内免费 | 6篇 |
专业分类
儿科学 | 20篇 |
妇产科学 | 8篇 |
基础医学 | 82篇 |
口腔科学 | 3篇 |
临床医学 | 100篇 |
内科学 | 105篇 |
皮肤病学 | 15篇 |
神经病学 | 52篇 |
特种医学 | 1篇 |
外科学 | 29篇 |
综合类 | 9篇 |
预防医学 | 21篇 |
眼科学 | 3篇 |
药学 | 355篇 |
中国医学 | 3篇 |
肿瘤学 | 53篇 |
出版年
2023年 | 2篇 |
2022年 | 17篇 |
2021年 | 13篇 |
2020年 | 29篇 |
2019年 | 37篇 |
2018年 | 32篇 |
2017年 | 35篇 |
2016年 | 38篇 |
2015年 | 39篇 |
2014年 | 59篇 |
2013年 | 101篇 |
2012年 | 42篇 |
2011年 | 57篇 |
2010年 | 47篇 |
2009年 | 48篇 |
2008年 | 37篇 |
2007年 | 28篇 |
2006年 | 29篇 |
2005年 | 20篇 |
2004年 | 20篇 |
2003年 | 18篇 |
2002年 | 22篇 |
2001年 | 10篇 |
2000年 | 5篇 |
1999年 | 5篇 |
1998年 | 5篇 |
1997年 | 3篇 |
1996年 | 7篇 |
1995年 | 9篇 |
1994年 | 2篇 |
1993年 | 3篇 |
1992年 | 4篇 |
1991年 | 2篇 |
1990年 | 4篇 |
1989年 | 7篇 |
1987年 | 3篇 |
1986年 | 1篇 |
1985年 | 3篇 |
1984年 | 1篇 |
1983年 | 1篇 |
1982年 | 2篇 |
1980年 | 3篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1977年 | 1篇 |
1976年 | 2篇 |
1973年 | 1篇 |
1972年 | 2篇 |
1971年 | 1篇 |
排序方式: 共有859条查询结果,搜索用时 0 毫秒
31.
32.
《Clinical therapeutics》2020,42(8):1595-1610.e5
PurposeThe symposium Health and Medicines in Indigenous Populations of America was organized by the Council for International Organizations of Medical Sciences (CIOMS) Working Group on Clinical Research in Resource-Limited Settings (RLSs) and the Ibero-American Network of Pharmacogenetics and Pharmacogenomics (RIBEF). It was aimed to share and evaluate investigators' experiences on challenges and opportunities on clinical research and pharmacogenetics.MethodsA total of 33 members from 22 countries participated in 2 sessions: RIBEF studies on population pharmacogenetics about the relationship between ancestry with relevant drug-related genetic polymorphisms and the relationship between genotype and phenotype in Native Americans (session 1) and case examples of clinical studies in RLSs from Asia (cancer), America (diabetes and women health), and Africa (malaria) in which the participants were asked to answer in free text their experiences on challenges and opportunities to solve the problems (session 2). Later, a discourse analysis grouping common themes by affinity was conducted.FindingsThe main result of session 1 was that the pharmacogenetics-related ancestry of the population should be considered when designing clinical studies in RLSs. In session 2, 21 challenges and 20 opportunities were identified. The social aspects represent the largest proportion of the challenges (43%) and opportunities (55%), and some of them seem to be common.ImplicationsThe main discussion points were gathered in the Declaration of Mérida/T'Hó and announced on the Parliament of Extremadura during the CIOMS-RIBEF meeting in 4 of the major Latin American autochthonous languages (Náhualth, Mayan, Miskito, and Kichwa). The declaration highlighted the following: (1) the relevance of population pharmacogenetics, (2) the sociocultural contexts (interaction with traditional medicine), and (3) the education needs of research teams for clinical research in vulnerable and autochthonous populations. 相似文献
33.
Kristin W. Weitzel Amanda R. Elsey Taimour Y. Langaee Benjamin Burkley David R. Nessl Aniwaa Owusu Obeng Benjamin J. Staley Hui-Jia Dong Robert W. Allan J. Felix Liu Rhonda M. Cooper-DeHoff R. David Anderson Michael Conlon Michael J. Clare-Salzler David R. Nelson Julie A. Johnson 《American journal of medical genetics. Part C, Seminars in medical genetics》2014,166(1):56-67
34.
James M. Hoffman Cyrine E. Haidar Mark R. Wilkinson Kristine R. Crews Donald K. Baker Nancy M. Kornegay Wenjian Yang Ching-Hon Pui Ulrike M. Reiss Aditya H. Gaur Scott C. Howard William E. Evans Ulrich Broeckel Mary V. Relling 《American journal of medical genetics. Part C, Seminars in medical genetics》2014,166(1):45-55
35.
Michael J Fusco Todd C Knepper Juliana Balliu Alex Del Cueto Jose M Laborde Sharjeel M Hooda Andrew S Brohl Marilyn M Bui J Kevin Hicks 《The oncologist》2022,27(1):e9
BackgroundCancer of unknown primary (CUP) comprises a heterogeneous collection of malignancies that are typically associated with a poor prognosis and a lack of effective treatment options. We retrospectively evaluated the clinical utility of targeted next-generation sequencing (NGS) among CUP patients to assist with diagnosis and identify opportunities for molecularly guided therapy.Patients and MethodsPatients with a CUP at Moffitt Cancer Center who underwent NGS between January 1, 2014 and December 31, 2019, were eligible for study inclusion. Next-generation sequencing results were assessed to determine the frequency of clinically actionable molecular alterations, and chart reviews were performed to ascertain the number of patients receiving molecularly guided therapy.ResultsNinety-five CUP patients were identified for analysis. Next-generation sequencing testing identified options for molecularly guided therapy for 55% (n = 52) of patients. Among patients with molecularly guided therapy options, 33% (n = 17) were prescribed a molecularly guided therapy. The median overall survival for those receiving molecularly guided therapy was 23.6 months. Among the evaluable patients, the median duration of treatment for CUP patients (n = 7) receiving molecular-guided therapy as a first-line therapy was 39 weeks. The median duration of treatment for CUP patients (n = 8) treated with molecularly guided therapy in the second- or later-line setting was 13 weeks. Next-generation sequencing results were found to be suggestive of a likely primary tumor type for 15% (n = 14) of patients.ConclusionNext-generation sequencing results enabled the identification of treatment options in a majority of patients and assisted with the identification of a likely primary tumor type in a clinically meaningful subset of patients. 相似文献
36.
37.
Rafael Genario Murilo S. de Abreu Ana C.V.V. Giacomini Konstantin A. Demin Allan V. Kalueff 《The European journal of neuroscience》2020,52(1):2586-2603
Sex is an important variable in biomedical research. The zebrafish (Danio rerio) is increasingly utilized as a powerful new model organism in translational neuroscience and pharmacology. Mounting evidence indicates important sex differences in zebrafish behavioral and neuropharmacological responses. Here, we discuss the role of sex in zebrafish central nervous system (CNS) models, their molecular mechanisms, recent findings and the existing challenges in this field. We also emphasize the growing utility of zebrafish models in translational neuropharmacological research of sex differences, fostering future CNS drug discovery and the search for novel sex‐specific therapies. Finally, we highlight the interplay between sex and environment in zebrafish models of sex‐environment correlations as an important strategy of CNS disease modeling using this aquatic organism. 相似文献
38.
39.
40.
Possible role of CYP2B6 genetic polymorphisms in ifosfamide‐induced encephalopathy: report of three cases 下载免费PDF全文
Thomas Duflot Aude Marie‐Cardine Céline Verstuyft Bruno Filhon Tony Pereira Nathalie Massy‐Guillemant Robinson Joannidès Jérémy Bellien Fabien Lamoureux 《Fundamental & clinical pharmacology》2018,32(3):337-342
Ifosfamide (IFA) is a potent alkylating antitumoral agent, but its use is limited by neurological side effects. IFA is a racemic mixture of two enantiomeric forms, R‐IFA and S‐IFA with a stereoselective metabolism by CYP3A4 and CYP2B6, leading either to bioactive or to toxic pathways. In three consecutive cases of pediatric patients who exhibited IFA‐induced encephalopathy (IIE), genotyping of clinically relevant single‐nucleotide polymorphisms associated with decreased CYP3A4 and CYP2B6 activities was performed. Genetic investigations revealed the presence of CYP2B6 rs4803419 (C>T) in one patient while the two others carried the CYP2B6*6 allelic variant. All patients carried CYP3A4 wild‐type genotype (CYP3A4*1/*1). Because CYP2B6‐deficient alleles may be responsible for an increased conversion of S‐IFA into neurotoxic metabolites, screening for CYP2B6 polymorphisms may help to avoid IIE and improve clinical outcomes. 相似文献